newsfilter
← Latest News
PR Newswire·

BioVaxys announces completed synthesis of its Pan-Sarbecovirus Vaccine candidate and launch of in vivo animal study

VANCOUVER, BC, Sept. 6, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced today that Millipore-Sigma, the contract manufacturer for its preclinical viral vaccine program, has complete